Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Phosphoinositides and PIPs01:42

Phosphoinositides and PIPs

Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
IP3/DAG Signaling Pathway01:11

IP3/DAG Signaling Pathway

Membrane lipids such as phosphatidylinositol (PI) are precursors for several membrane-bound and soluble second messengers. Specific kinases phosphorylate PI and produce phosphorylated inositol phospholipids. One such inositol phospholipids are the  phosphatidylinositol-4,5 bisphosphate [PI(4,5)P2], present in the inner half of the lipid bilayer. Upon ligand binding, GPCR stimulates Gq proteins to turn on phospholipase Cꞵ. Activated phospholipase Cꞵ cleaves PI(4,5)P2 and produces two-second...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A different alternative to warfarin?

Blood advances·2026
Same author

The first clotting factor is also the last.

Blood·2026
Same author

Platelet Polyphosphate Signals Through NFκB to Induce Myofibroblast Differentiation.

Biomolecules·2025
Same author

Cryo-EM structure of the tissue factor/factor VIIa complex with a factor X mimetic reveals a novel allosteric mechanism.

Blood·2025
Same author

ECMO-induced coagulopathy: strategic initiatives for research and clinical practice (a workshop report of the NHLBI).

Blood vessels, thrombosis & hemostasis·2025
Same author

Crystal structure of coagulation factor XII N-terminal domains 1-5.

Acta crystallographica. Section D, Structural biology·2025

Related Experiment Video

Updated: May 8, 2026

Identification of Inositol Phosphate or Phosphoinositide Interacting Proteins by Affinity Chromatography Coupled to Western Blot or Mass Spectrometry
08:07

Identification of Inositol Phosphate or Phosphoinositide Interacting Proteins by Affinity Chromatography Coupled to Western Blot or Mass Spectrometry

Published on: July 26, 2019

One inositol ring to rule thrombosis.

James H Morrissey1

  • 1University of Illinois at Urbana-Champaign.

Blood
|August 24, 2013
PubMed
Summary

Knocking out an inositol kinase in mice reduces polyphosphate in platelet granules. This finding diminishes blood clotting and offers protection against thrombosis.

Area of Science:

  • Biochemistry
  • Hematology
  • Molecular Biology

Background:

  • Platelet dense granules store key molecules regulating hemostasis and thrombosis.
  • Polyphosphate is a molecule found in platelet dense granules with known roles in coagulation.
  • Inositol kinases are enzymes involved in cellular signaling and metabolism.

Purpose of the Study:

  • To investigate the role of inositol kinase in regulating polyphosphate levels within platelet dense granules.
  • To determine the impact of altered polyphosphate levels on platelet function, hemostasis, and thrombosis.

Main Methods:

  • Generation of knockout mice lacking a specific inositol kinase.
  • Analysis of polyphosphate content in platelet dense granules from knockout and wild-type mice.

More Related Videos

Absolute Quantitation of Inositol Pyrophosphates by Capillary Electrophoresis Electrospray Ionization Mass Spectrometry
09:22

Absolute Quantitation of Inositol Pyrophosphates by Capillary Electrophoresis Electrospray Ionization Mass Spectrometry

Published on: August 13, 2021

Preparation of Quality Inositol Pyrophosphates
10:34

Preparation of Quality Inositol Pyrophosphates

Published on: September 3, 2011

Related Experiment Videos

Last Updated: May 8, 2026

Identification of Inositol Phosphate or Phosphoinositide Interacting Proteins by Affinity Chromatography Coupled to Western Blot or Mass Spectrometry
08:07

Identification of Inositol Phosphate or Phosphoinositide Interacting Proteins by Affinity Chromatography Coupled to Western Blot or Mass Spectrometry

Published on: July 26, 2019

Absolute Quantitation of Inositol Pyrophosphates by Capillary Electrophoresis Electrospray Ionization Mass Spectrometry
09:22

Absolute Quantitation of Inositol Pyrophosphates by Capillary Electrophoresis Electrospray Ionization Mass Spectrometry

Published on: August 13, 2021

Preparation of Quality Inositol Pyrophosphates
10:34

Preparation of Quality Inositol Pyrophosphates

Published on: September 3, 2011

  • Assessment of hemostatic function and thrombosis models in knockout mice.

    • Main Results:

    • Inositol kinase knockout mice exhibited significantly diminished polyphosphate levels in platelet dense granules.
    • Reduced polyphosphate levels correlated with impaired platelet aggregation and prolonged bleeding times.
    • Knockout mice showed a significant reduction in thrombus formation in vivo.

    Conclusions:

    • Inositol kinase plays a crucial role in the accumulation of polyphosphate in platelet dense granules.
    • Diminished polyphosphate levels due to inositol kinase deficiency impair hemostasis and confer protection against thrombosis.
    • Targeting inositol kinase or polyphosphate metabolism may represent a novel therapeutic strategy for thrombotic disorders.